<DOC>
	<DOCNO>NCT01275352</DOCNO>
	<brief_summary>This study consist middle-aged Caucasian non-failing subject high blood pressure homozygous gene confers increase risk develop heart failure , Glycine 83 variant Ka renal chloride channel ( ClC-Ka Gly/Gly 83 ) , middle-aged Caucasian non-failing hypertensive subject lack heart failure risk gene , wild-type Arginine 83 Ka renal chloride channel ( ClC-Ka Arg/Arg 83 ) . Subjects standard therapy high blood pressure angiotensin convert inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) randomize additional treatment eplerenone ( aldosterone antagonist ) placebo , assess change echocardiographic leave ventricular hypertrophy ( LVMI ) . Secondary endpoint assess leave ventricular remodel echocardiographic variable . The investigator hypothesize subject homozygous CLCNKA risk allele great response eplerenone term reduction LVMI lack risk allele .</brief_summary>
	<brief_title>CLCNKA ( Ka Renal Chloride ChannelClC-Ka ) Polymorphism Effects Hypertrophy Regression</brief_title>
	<detailed_description>The screening phase involve identify Caucasian hypertensive patient homozygous ClC-Ka Gly/Gly83 ClC-Ka Arg/Arg 83 allele . All patient background therapy angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) least mid range dosing . If patient recommend dose ACE ARB must titrate stable midrange dose ACEI ARB least 4 week enter study . There 2 treatment phase . Phase 1 4 week duration consist randomization one table eplerenone ( 25 mg ) match placebo . On week 2 patient titrate two tablet eplerenone ( 50 mg ) match placebo , achieve target dose 50 mg eplerenone . If patient tolerate two tablet eplerenone match placebo titrate one tablet eplerenone match placebo . The target BP study medication &lt; 130/80 mmHg . After patient titrate maximally tolerate dose study medication , background hypertension therapy adjust reach target BP &lt; 130/80 mmHg end week 4 . Phase 2 52 week duration ass effect placebo eplerenone LV hypertrophy . Serum potassium monitor throughout study , necessary , dose eplerenone titrate necessary .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Caucasians hypertension homozygous ClCKa Gly/Gly83 ClCKa Arg/Arg 83 allele . 2 . Male nonpregnant female age 40 80 year . 3 . Hypertension , define currently take high blood pressure medication medication SDP &gt; 140 DBP &gt; 90 . 4 . Ejection fraction &gt; 50 % method within 6 month screen visit . 5 . The Investigator must obtain write informed consent subject screen study . 6 . Subject stable dose ACE ARB moderate dosing least 4 week randomization . 1 . History heart failure preserve depressed ejection fraction . 2 . Creatinine clearance &lt; 45 mL/min base CockcroftGault formula ( Appendix C ) . 3 . Pregnancy 4 . Life expectancy le 12 month . 5 . Planned cardiac surgery percutaneous cardiac intervention within 3 month . 6 . Serum potassium &gt; 5.5 mEq/L . 7 . History hyperkalemia ( K &gt; 6.0 mEq/L ) eplerenone spironolactone . 8 . Myocardial infarction stroke within 3 month screen . 9 . Evidence clinical instability ( hypotension , arrhythmia , unstable angina etc. ) . 10 . Subjects require Ksparing diuretic spironolactone . 11 . Concomitant use potent inhibitor CYP3A4 include ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir drug note Contraindications , Warnings Precautions section label potent CYP3A4 inhibitor 12 . Known hypersensitivity eplerenone spironolactone . 13 . Evidence current alcohol drug abuse Severe organic disorder surgery disease gastrointestinal tract opinion Investigator may interfere absorption elimination study drug . 14 . Psychoses behavioral condition opinion Investigator would limit study compliance . 15 . Subjects receive investigational medication use investigational device within 30 day prior first dose study drug subject actively participate investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>heart failure</keyword>
</DOC>